A recent study, led by Orouji at al., revealed that the expression and amplification rate of SETDB1 may serve as an individual prognostic biomarker in CM, with increased levels of SETB1 protein being associated with metastasis and lower patient survival rates [131]. Here, SETDB1 is linked to cutaneous mastocytosis.